8-K: Avalo Therapeutics Secures Expanded $75 Million At-The-Market Equity Offering with TD Cowen, Terminates Previous $50 Million Facility

Avalo Therapeutics, Inc. has entered into a new sales agreement with TD Securities (USA) LLC to offer and sell up to $75.0 million of its common stock through an At-The-Market offering, replacing its prior $50.0 million facility with Oppenheimer & Co. Inc.

Summary

• Avalo Therapeutics, Inc. (AVTX) has established a new At-The-Market (ATM) equity offering program with TD Securities (USA) LLC (TD Cowen), allowing the company to sell up to $75.0 million of its common stock from time to time.
• TD Cowen will act as the sales agent for the offering and will receive a commission of up to 3.0% of the gross proceeds from the sale of shares.
• This new agreement replaces a previous ATM facility of up to $50.0 million with Oppenheimer & Co. Inc., which Avalo Therapeutics terminated on June 3, 2025, effective no later than June 4, 2025, without incurring any termination penalties.
• The issuance and sale of shares under the new agreement will be conducted pursuant to the company's existing Registration Statement on Form S-3, which was declared effective on May 2, 2023, and a prospectus supplement filed on June 5, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the ATM offering introduces potential dilution for shareholders, securing a larger capital raising facility (from $50M to $75M) with a new agent is a crucial step for a biotech company to ensure liquidity and fund ongoing operations and development. The absence of termination penalties for the previous agreement is also a favorable point. It represents a necessary and strategically sound financial maneuver.

Positives

• The company has secured a larger potential capital raise amount, increasing from a previous $50.0 million facility to a new $75.0 million facility, indicating improved access to capital.
• Avalo Therapeutics successfully terminated its prior sales agreement with Oppenheimer & Co. Inc. without incurring any termination penalties, demonstrating efficient financial management.
• The establishment of an ATM offering provides the company with financial flexibility to raise capital opportunistically based on market conditions, rather than through a single, large offering.

Negatives

• The At-The-Market offering, if fully utilized, will result in significant dilution for existing shareholders due to the issuance of new common stock.
• TD Cowen will receive a commission of up to 3.0% of the gross proceeds, which represents a cost to the company for raising capital.

Risks

• **Shareholder Dilution**: The sale of common stock under the ATM program will increase the number of outstanding shares, potentially diluting the ownership interest and earnings per share of existing shareholders.
• **Market Conditions**: The company's ability to raise the full $75.0 million will depend on market demand for its common stock and prevailing market prices, which are subject to volatility.
• **Stock Price Volatility**: Continuous sales of shares into the market through an ATM program could exert downward pressure on the company's stock price.
• **Reliance on Agent Efforts**: TD Cowen is obligated to use only 'commercially reasonable efforts' to sell the shares, meaning there is no guarantee that the company will be able to raise the desired amount of capital.
• **Regulatory Compliance**: The company must continuously comply with SEC regulations, including timely filings and maintaining an effective registration statement, to continue the offering.

Future Outlook

The document indicates that Avalo Therapeutics may offer and sell shares of its common stock from time to time through the new At-The-Market offering, providing an opportunistic and flexible approach to future capital raising. The company is not obligated to make any sales, allowing it to manage its financing needs based on market conditions and operational requirements.

Industry Context

At-The-Market (ATM) offerings are a common and flexible financing tool widely utilized by biotechnology and pharmaceutical companies, particularly those in clinical development stages, to fund ongoing research and development, clinical trials, and general corporate purposes. This method allows companies to raise capital incrementally over time, minimizing immediate pricing pressure and market disruption often associated with traditional underwritten offerings. Avalo Therapeutics' move to a larger ATM facility aligns with industry trends of companies seeking continuous access to capital to support their long-term strategic objectives and pipeline advancements.

Comparison to Industry Standards

• The use of an At-The-Market (ATM) offering is a standard and widely accepted financing mechanism in the biotechnology and pharmaceutical sectors, particularly for companies with ongoing R&D needs and fluctuating capital requirements.
• The commission rate of up to 3.0% payable to TD Cowen is within the typical range for ATM agreements in the industry, which commonly fall between 1% and 3%, depending on factors such as company size, trading liquidity, and market conditions.
• The increase in the potential capital raise from $50.0 million to $75.0 million suggests either growing capital needs for Avalo Therapeutics' pipeline or an improved market perception and ability to attract larger financing, which is a positive signal compared to smaller, more constrained facilities seen in some industry peers.
• The termination of the previous agreement without penalty is a favorable outcome, indicating a clean transition and avoiding additional costs often associated with breaking financial contracts.

Stakeholder Impact

• **Shareholders**: Will experience potential dilution of their ownership stake and earnings per share as new common stock is issued under the ATM program.
• **Company Operations**: The capital raised will provide essential funding for Avalo Therapeutics' ongoing research and development activities, clinical trials, and general corporate expenses, supporting its long-term strategic goals.
• **Creditors**: A stronger cash position from the capital raise could improve the company's financial stability and ability to meet its obligations.

Next Steps

• Avalo Therapeutics may commence selling shares of its common stock under the new At-The-Market program with TD Cowen, subject to market conditions and the company's discretion.
• The company will continue to file prospectus supplements with the SEC as required by Rule 424(b) for sales made under the agreement.
• Avalo Therapeutics will disclose the number of Placement Shares sold and net proceeds in its quarterly reports on Form 10-Q and annual reports on Form 10-K.
• The company will furnish officer certificates, legal opinions, and comfort letters to TD Cowen on specified 'Bring-Down Dates' (e.g., filing of annual/quarterly reports, or certain amendments to the registration statement).

Key Dates

Recommendation

Keywords

Avalo Therapeutics, AVTX, At-The-Market offering, ATM offering, equity financing, capital raise, common stock, SEC filing, 8-K, TD Cowen, Oppenheimer, dilution, biotechnology, pharmaceuticals